title: Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
abstract: OBJECTIVE
  To evaluate the effect of oral eplerenone on subretinal fluid, visual acuity, and choroidal thickness in patients with chronic central serous chorioretinopathy (CSCR).
  
  
  METHODS
  Retrospective review of all patients (14 eyes of 14 patients) monitored for a minimum of 3 months with chronic CSCR who were treated with oral eplerenone in a single multi-physician retina practice. Visual acuity, dilated funduscopic examination, and spectral-domain ocular coherence tomography (OCT) with enhanced depth imaging (EDI) were obtained at each visit. Measurement of subfoveal fluid (SFF) height and choroidal thickness were performed. Two-tailed paired t test was used to calculate statistical significance of pre- and post-treatment variables.
  
  
  RESULTS
  At 1 month, 10 of 14 eyes had decreased SFF height on OCT and two eyes had complete resolution of SFF. Mean SFF height decreased from 130 µm to 62 µm (P = .05). Mean choroidal thickness decreased from 315 µm to 282 µm (P = .07). Mean visual acuity improved from logMAR 0.41 to 0.40. At 3 months, 13 of 14 (93%) had decreased SFF on OCT, and nine eyes (64%) had complete resolution of SFF. Mean SFF height decreased to 21 µm (P = .004). Mean choroidal thickness decreased to 253 µm (P = .10). Mean visual acuity improved to logMAR 0.28 (P = .02).
  
  
  CONCLUSIONS
  Oral eplerenone may be effective in treating patients with chronic CSCR.
authors.forename: David A
authors.initials: DA
authors.lastname: Salz
authors.forename: John D
authors.initials: JD
authors.lastname: Pitcher
authors.forename: Jason
authors.initials: J
authors.lastname: Hsu
authors.forename: Carl D
authors.initials: CD
authors.lastname: Regillo
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Fineman
authors.forename: Kevin S
authors.initials: KS
authors.lastname: Elliott
authors.forename: James F
authors.initials: JF
authors.lastname: Vander
authors.forename: David H
authors.initials: DH
authors.lastname: Fischer
authors.forename: Marc J
authors.initials: MJ
authors.lastname: Spirn
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D056833:Central Serous Chorioretinopathy / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D002829:Choroid / Q000473:pathology; D002908:Chronic Disease; D000077545:Eplerenone; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D012189:Retrospective Studies; D013148:Spironolactone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D058471:Subretinal Fluid / Q000187:drug effects; D041623:Tomography, Optical Coherence; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D000077545:Eplerenone